ProShare Advisors
CADL icon

ProShare Advisors’s Candel Therapeutics CADL Stock Holding History

ProShare Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Buy
+10,700
New +$80.8K ﹤0.01% 1759
2026
Q1 		– Sell
-10,433
Closed -$58.9K – 1890
2025
Q4 		$58.9K Buy
+10,433
New +$56.1K ﹤0.01% 1939

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ProShare Advisors's CADL Position: Q2 2026 in Review

ProShare Advisors opened a new position in Candel Therapeutics (CADL) in Q2 2026: 10,700 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #1759 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in CADL as recently as Q4 2025.

ProShare Advisors first reported a position in CADL in Q4 2025 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • ProShare Advisors held 10,700 shares of Candel Therapeutics worth $110K as of Q2 2026.
  • Candel Therapeutics was a new ProShare Advisors position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1759 holding.
  • ProShare Advisors first reported a position in Candel Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.